GH Research

GHRSPhase 2

Dublin, IrelandFounded 2018ghres.com

GH Research is pioneering a new class of psychiatric treatments based on its proprietary mebufotenin (5-MeO-DMT) platform, targeting difficult-to-treat depression subtypes. Early clinical data from its lead inhaled candidate, GH001, show promising remission rates and rapid onset of action within hours. With a cleared regulatory path and a growing intellectual property portfolio, the company is advancing multiple formulations toward late-stage development in major depressive disorders.

Market Cap

$866.6M

Founded

2018

Focus

Small Molecules

GHRS · Stock Price

USD 13.973.87 (-21.69%)

Historical price data

AI Company Overview

Technology Platform

Proprietary mebufotenin (5-MeO-DMT) platform with multiple formulation and delivery methods (inhalation, IV) designed to induce ultra-rapid and durable remission in psychiatric disorders with a single-day treatment paradigm.

Pipeline Snapshot

8 drugs in pipeline

Drug	Indication	Stage
GH001	Postpartum Depression	Phase 2
GH001 + Placebo	Treatment-resistant Depression	Phase 2
GH001	Bipolar II Disorder	Phase 2
5 Methoxy N,N Dimethyltryptamine	Treatment Resistant Depression	Phase 1/2
5 Methoxy N,N Dimethyltryptamine	Healthy Volunteers	Phase 1

Funding History

Total raised: $300M

IPO$175MUndisclosedJul 16, 2021

Series A$125MRA Capital ManagementMar 15, 2021

Opportunities

Large and growing market for treatment-resistant depression and related mood disorders where current therapies have significant limitations.

Ultra-rapid onset of action and single-day treatment paradigm could disrupt standard care and expand into acute intervention settings.

Platform potential with multiple formulations (inhalation, IV) and indications (TRD, BDII, PPD) provides multiple value inflection points.

Risk Factors

Clinical development risk in upcoming Phase 3 trials; regulatory uncertainty despite lifted clinical hold; market acceptance challenges for a psychedelic-derived therapy; intense competition from both pharmaceutical and biotechnology companies developing novel depression treatments; manufacturing and supply chain complexities for a controlled substance.

Competitive Landscape

Competes with Johnson & Johnson's Spravato (esketamine), Compass Pathways' psilocybin program, Sage Therapeutics' zuranolone, and other novel antidepressant approaches. Differentiation lies in ultra-rapid (2-hour) onset of action, durable effects from single-day dosing, and a favorable early tolerability profile without requirement for concomitant psychotherapy.

Publications

Pipeline